Cargando…

Azvudine (FNC): a promising clinical candidate for COVID-19 treatment

Detalles Bibliográficos
Autores principales:	Yu, Bin, Chang, Junbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547293/ https://www.ncbi.nlm.nih.gov/pubmed/33040075 http://dx.doi.org/10.1038/s41392-020-00351-z

Ejemplares similares

The first Chinese oral anti-COVID-19 drug Azvudine launched
por: Yu, Bin, et al.
Publicado: (2022)

FNC efficiently inhibits mantle cell lymphoma growth
por: Zhang, Yan, et al.
Publicado: (2017)

The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses
por: Xu, Na, et al.
Publicado: (2020)

A promising vaccine candidate against COVID-19
por: Wang, Xiwei, et al.
Publicado: (2020)

Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19
por: da Silva, Renato Martins, et al.
Publicado: (2023)

A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study
por: Ren, Zhigang, et al.
Publicado: (2020)

Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2021)

FNC: An Advanced Anticancer Therapeutic or Just an Underdog?
por: Fayzullina, Daria, et al.
Publicado: (2022)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
por: Zhao, Xiang, et al.
Publicado: (2023)

Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023)

Surrogate cytokine agonists: promising agents against COVID-19
por: Lin, Zemin, et al.
Publicado: (2022)

Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients
por: de Souza, Sávio Bastos, et al.
Publicado: (2023)

Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants
por: Zhang, Xi, et al.
Publicado: (2023)

Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials
por: Zhu, Ke-Wei
Publicado: (2023)

Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
por: Gao, Yuan, et al.
Publicado: (2023)

FcγRIIb blockage: a promising immunotherapy target for severe COVID-19
por: He, Xuemei, et al.
Publicado: (2021)

Constrained surfaces: promising therapeutic targets for COVID-19 determined by systematically mutational analysis
por: Wang, Manni, et al.
Publicado: (2021)

Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis
por: Chen, Zhaoyan, et al.
Publicado: (2023)

Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study
por: Zong, Kaican, et al.
Publicado: (2023)

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
por: Mao, Manyun, et al.
Publicado: (2023)

Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase
por: Xu, Yechun, et al.
Publicado: (2020)

In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
por: Moreno, Sandra, et al.
Publicado: (2015)

Prevention and treatment of COVID‐19 disease by controlled modulation of innate immunity
por: Schijns, Virgil, et al.
Publicado: (2020)

Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
por: Abd El-Aziz, Tarek Mohamed, et al.
Publicado: (2020)

Impact of flexible noise control (FNC) image processing parameters on portable chest radiography
por: Kirby, Krystal M., et al.
Publicado: (2022)

Potential mechanisms by which impaired ketogenesis links metabolism to T‐cell dysfunction in patients with severe COVID‐19
por: Wang, Bin, et al.
Publicado: (2022)

COVID-19 and Tuberculosis
por: Yang, Heng, et al.
Publicado: (2020)

Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
por: Zhang, Jin-Lan, et al.
Publicado: (2021)

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
por: Sun, Yuming, et al.
Publicado: (2023)

Combating COVID-19 with Chloroquine
por: Hong, Wanjin
Publicado: (2020)

Early treatment for COVID-19
por: Du Toit, Andrea
Publicado: (2023)

The Application of Corticosteroids in COVID-19: A Two-edged Sword
por: Li, Na, et al.
Publicado: (2020)

Dietary intervention, a promising adjunct for cancer therapy
por: Shi, Rongchen, et al.
Publicado: (2020)

The putative mechanism of lymphopenia in COVID-19 patients
por: Wang, Xinling, et al.
Publicado: (2022)

mRNA vaccine shows promise in autoimmunity
por: Flemming, Alexandra
Publicado: (2021)

Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China
por: Yang, Jing, et al.
Publicado: (2020)

Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody
por: Li, Fang, et al.
Publicado: (2020)

Proteomics promises a new era of precision cancer medicine
por: Wu, Chong, et al.
Publicado: (2019)

A next‐generation vaccine for broader and long‐lasting COVID‐19 protection
por: Xi, Jinxiang, et al.
Publicado: (2022)

Pandemic number five – Latest insights into the COVID-19 crisis
por: Häfner, Sophia Julia
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8rli7aq2kjkapfqjnm4ap2j2to